News for Healthier Living

From Mutation to Medicine: How Neoantigen Dendritic Cell Vaccines Are Reshaping Cancer Immunotherapy

A new generation of personalized cancer vaccines is taking shape through the use of neoantigen-based dendritic cell (DC) vaccines. These vaccines aim to train the immune system to recognize tumor-specific mutations, known as neoantigens, and trigger targeted immune responses against cancer cells. By tailoring vaccine components to the genetic profile of an individual's tumor, neoantigen-based DC vaccines offer a personalized immunotherapy strategy that may help address the challenges of tumor heterogeneity and variable treatment response observed with conventional therapies. Recent clinical studies across liver, lung, gastric, and ovarian cancers have shown that patient-derived DC vaccines can trigger strong, durable immune responses, delay tumor recurrence, and extend survival. This individualized immunotherapy marks a crucial step toward precision cancer treatment.

November 19, 2025


November 19 2025

November 18 2025

November 17 2025

November 16 2025

November 15 2025

November 14 2025

November 13 2025

November 12 2025

November 11 2025

November 10 2025

November 9 2025

November 8 2025

November 7 2025

November 6 2025

November 5 2025